MedscapeSeptember 24, 2026
Tirzepatide: Modest Weight Regain, Sustained Glycemic Gains Over 3 Years
Reported by Medscape. Read the original →
What the story says
The headline reports that tirzepatide is associated with modest weight regain while maintaining sustained glycemic improvements over a three-year period.
Summarised by a model from Medscape's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.
On file here
Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.
TirzepatideA · Human clinical
- Clinical performance of monolithic and veneered zirconia three-unit posterior FDPs: A five-year multicenter randomized controlled trial.Human · RCT · 2026
- Insights from a double-blind, randomized, direct-to-participant intervention trial for Long COVIDHuman · RCT · 2026
- Evaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes.Human · RCT · 2026
What the headline doesn't tell you
- Tirzepatide has 29 studies on file, 16 of them in humans, the newest published 2026.
Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.